Diabetes Mellitus Type 2 Flashcards

1
Q

Biguanides- Available Drugs

A

Metformin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Metformin- Mech of Action

A

INHIBIT COMPLEX I OF MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION–> INCREASE AMP/ATP RATIO–> ACTIVATE AMP DEPENDENT KINASE (AMPK)–> REDUCE HEPATIC GLUCONEOGENESIS/INCREASE IN INSULIN SENSITIVITY IN MUSCLE AND ADIPOSE–> INCREASE GLUCOSE UTILIZATION–> LOWER FASTING PLASMA GLUCOSE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Metformin- Kinetics

A

HbA1c decrease= 1.5%

duration= 6 hr

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Metformin- Clinical Use

A

DOC FOR ALL TYPE II DM THAT ISN’T CONTROLLED BY DIET AND EXERCISE ALONE

LOWERS FASTING GLUCOSE

requires the presence of insulin for its effects
improves lipid profiles (decreases FFA, TGs, LDL, increases HDL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Metformin- Side Effects/Contraindications

A

DOES NOT CAUSE WEIGHT GAIN

generally well tolerated
can inhibit absorption of B12

POTENTIALLY FATAL LACTIC ACIDOSIS (DEEP, RAPID BREATHING, VOMITING, ABDOMINAL PAIN, WEAKNESS OF LEGS AND ARMS)–> USUALLY SEEN IN RENAL INSUFFICIENCY, CHF, MI, HYPOXIC STATE

CONTRAINDICATED in: 
pregnancy
IMPAIRED LIVER OR RENAL FUNCTION
elderly
patients taking iodinated contrast agent
other conditions predisposing to lactic acidosis- CHF, MI, shock, septicemia, hypoxic/ischemic state, serious illness
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Thiazolidinediones- Available Drugs

A

Pioglitazone

Rosiglitazone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Pioglitazone, Rosiglitazone- Mech of Action

A

AGONIST FOR PPAR-G TRANSCRIPTION FACTOR–> INCREASE GLUT4 EXPRESSION, ADIPONECTIN, FFA UPTAKE, ADIPOSE REMODELING AND DECREASE TNF-A/RESISTIN–> INCREASE INSULIN SENSITIVITY IN ADIPOSE, MUSCLE, LIVER–> INCREASE GLUCOSE UTILIZATION

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Pioglitazone, Rosiglitazone- Kinetics

A

HbA1c decrease= 0.5%

duration= weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Pioglitazone, Rosiglitazone- Clinical Use

A

LOWERS FASTING GLUCOSE
lowers TGs

monotherapy or in combination with metformin, sulfonylureas, or insulin for DM 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Pioglitazone, Rosiglitazone- Side Effects/Contraindications

A

SUB-Q WEIGHT GAIN

FLUID RETENTION–>PERIPHERAL EDEMA–>RISK OF HEART FAILURE

ROSIGLITAZONE CAN CAUSE MI AND CARDIOVASCULAR DEATH = not on the market anymore

decrease bone density–> fracture risk in women
hepatotoxicity

CONTRAINDICATED IN LIVER DISEASE, HEART FAILURE, CVD, preganancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Sulfonylureas- Available Drugs

A

2nd Gen:
Chlorpropamide
Tolbutamide

3rd Gen:
Glimepiride
Glyburide
Glipizide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Sulfonylureas- Mech of Action

A

INHIBIT K CHANNELS IN B-CELLS–> INCREASED [K]INTRACELLULAR–> MEMBRANE DEPOLARIZATION–> OPEN CA CHANNEL–> INCREASE [CA]INTRACELLULAR–> INCREASE SECRETION OF INSULIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Sulfonylureas- Kinetics

A

LONG DURATION OF ACTION
metabolized by liver and excreted in kidney

HbA1c decrease= 1.5%
duration= 14-24 hrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Sulfonylureas- Clinical Use

A

LOWERS FASTING GLUCOSE

dependent on B-cell function- most effective in patients that have had diabetes for less than 10 years, still have functional B cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Sulfonylureas- Side Effects/Contraindications

A

HYPOGLYCEMIA especially in liver/renal dysfunction and the elderly

weight gain

CONTRAINDICATED IN:
IMPAIRED RENAL/HEPATIC FUNCTION
elderly
DM 1
pregnancy
lactation
sulfa allergies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Sulfonylureas- Drug Rxns

A

High protein binding- interaction with other protein binders (Salicylates, B-blockers, warfarin, fibrates)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Meglitinides- Available Drugs

A

Nateglinide

Repaglinide

18
Q

Nateglinide, Repaglinide- Mech of Action

A

INHIBIT K CHANNELS IN B-CELLS–> INCREASED [K]INTRACELLULAR–> MEMBRANE DEPOLARIZATION–> OPEN CA CHANNEL–> INCREASE [CA]INTRACELLULAR–> INCREASE SECRETION OF INSULIN

19
Q

Nateglinide, Repaglinide- Kinetics

A

SHORTER ACTING, FASTER ONSET

HbA1c decrease= 1-1.5%
duration= 2-4 hrs

20
Q

Nateglinide, Repaglinide- Clinical Use

A

CONTROL POSTPRANDIAL GLUCOSE ELEVATIONS

should be taken with or shortly before meal

21
Q

Nateglinide, Repaglinide- Side Effects/Contraindications

A

Hypoglycemia, weight gain

CONTRAINDICATED IN:
LIVER DISEASE
pregnancy

22
Q

GLP-1 Homologs- Available Drugs

A

Exenatide

Liraglutide

23
Q

Exenatide, Liraglutide- Mech of Action

A

BIND GLP-1 RECEPTOR ON PANCREATIC B-CELLS–> INCREASE GLUCOSE INDUCED INSULIN RELEASE/DECREASE GLUCAGON RELEASE/INCREASE B-CELL REGENERATION/INCREASE SATIETY

24
Q

Exenatide, Liraglutide- Kinetics

A

injected SubQ twice daily

HbA1c decrease= 0.5-1%
duration= 6-15 hrs

25
Q

Exenatide, Liraglutide- Clinical Use

A

DECREASE FASTING GLUCOSE
DECREASE POSTPRANDIAL GLUCOSE

promotes weight loss

alternative to starting insulin in patients not controlled with metformin, sulfonylurea, or both

26
Q

Exenatide, Liraglutide- Side Effects/Contraindications

A

Frequent nausea, vomiting, diarrhea
Little chance of hypoglycemia

BLACK BOX WARNING FOR RARE PANCREATITIS

27
Q

DPP-IV Inhibitors- Available Drugs

A

Sitagliptin

Saxagliptin

28
Q

Sitagliptin, Saxagliptin- Mech of Action

A

INACTIVATES DPP-IV, THE GLP-1 PEPTIDASE= INCREASES ACTIONS OF GLP-1

29
Q

Sitagliptin, Saxagliptin- Kinetics

A

PO once daily

HbA1c decrease= 0.48-0.61%
duration= 24 hrs

30
Q

Sitagliptin, Saxagliptin- Clinical Use

A

DECREASE FASTING GLUCOSE
DECREASE POSTPRANDIAL GLUCOSE

monotherapy or adjuvant with metformin or thiazolidinedione

31
Q

Sitagliptin, Saxagliptin- Side Effects/Contraindications

A

little risk of hypoglycemia

BLACK BOX WARNING FOR RARE PANCREATITIS

32
Q

Alpha-glucosidase Inhibitors- Available Drugs

A

Acarbose

Miglitol

33
Q

Acarbose, Miglitol- Mech of Action

A

INHIBIT A-GLUCOSIDASE–>PREVENT DIGESTION OF CARBOHYDRATES–> DECREASE GLUCOSE ABSORPTION

34
Q

Acarbose, Miglitol- Kinetics

A

HbA1c decrease= 0.5-0.8%

duration= 3-4 hrs

35
Q

Acarbose, Miglitol- Clinical Use

A

DECREASE POSTPRANDIAL GLUCOSE

less potent than other drugs- not considered a first line drug

36
Q

Acarbose, Miglitol- Side Effects/Contraindications

A

no risk of hypoglycemia

abdominal pain, flatulence

CONTRAINDICATED IN:
IBD
CHRONIC INTESTINAL DISEASE
COLONIC ULCERATION OR OBSTRUCTION

37
Q

Amylin Mimetic- Available Drugs

A

Pramlintide

38
Q

Pramlintide- Mech of Action

A

MIMIC ENDOGENOUS AMYLIN–> CONTRIBUTE TO POSTPRANDIAL GLUCOSE CONTROL- DECREASE GLUCAGON RELEASE, DECREASE HEPATIC GLUCONEOGENESIS, SLOW GASTRIC EMPTYING, INCREASE SATIETY

39
Q

Pramlintide- Kinetics

A

injected

HbA1c decrease= 0.5-0.7%
duration= 2-3 hrs

40
Q

Pramlintide- Clinical Use

A

adjuvant to insulin for DM type 1 or type 2

DECREASE POSTPRANDIAL GLUCOSE
promote weight loss

41
Q

Pramlintide- Side Effects/Contraindications

A

nausea

hypoglycemia, especially with insulin- need to reduce insulin dose 50%